Using #biomarkers to identify patients with mild persistent #asthma could represent a huge step toward better #treatment. New research led by pediatric allergist Ronina Covar, MD, looks to do just that. Learn more about her study: https://lnkd.in/gwKFqe98
National Jewish Health’s Post
More Relevant Posts
-
🧬 Achieving Precision Medicine in Pediatric Allergic Asthma: Challenges and Opportunities 🩺 One-size-fits-all.... or does it? 🤨🤔 Did you know that asthma is the most common chronic disease among children? 🧸 The World Health Organization reports that asthma had affected ~262 million people in 2019 and caused 455,000 deaths! 😷 Allergic asthma in particular, is triggered by aeroallergens which activate the immune response. The severity of the disease depends on a variety of factors like a patient's genetics, environmental exposures, and ethnicity 🧬. This leads to heterogenicity in clinical diagnosis and treatment responses. Thus, the typical "one-fits-all" approach provided by healthcare providers may no longer be effective and may cause serious side effects. 🩻 As the field of precision medicine continues to expand, with some approaches already in use today, it is crucial to recognize and address the complexities and challenges it presents. This is vital to develop a safe and effective treatment option for pediatric asthma 🩺. This poster highlights three potential gaps in the application of precision medicine for pediatric asthma, encompassing its challenges and limitations associated with the proposed solutions! Group Members: Fatimatulzahraa Afif Abdulqader Al Gailani Chloe Chuah Adeline Glory Eimaan Aisya Ahmad Mustaffa Batrisyia Dania Binti Kamal Hamzah Jailany Lecturer: Kavita Reginald School: Sunway University, School of Medical and Life Sciences, Sunway University #SunwayUniversity #SunwaySchoolofMedicalandLifeSciences #DepartmentofBiologicalSciences #Immunology #Allergy #PrecisionMedicine #BIO3094
To view or add a comment, sign in
-
-
“Real-world Effectiveness of Statin Therapy in Adult Asthma" is published in The Journal of Allergy and Clinical Immunology: In Practice (2023 IF: 9.4). Analyzed 10 years of asthma patient data and found that the inflammation-modulating effects of statins had a significant effect on asthma control. The analysis was performed using the PLE package in OMOP-CDM and a linear mixed model. Thanks to our team (Professor JaeHyuk Jang, Chungsoo Kim, Professor Eunyoung Angela Lee, Professor Rae Woong Park, and the former president of our hospital Hae Sim Park).
Real-world Effectiveness of Statin Therapy in Adult Asthma
sciencedirect.com
To view or add a comment, sign in
-
FDA expands dupilumab for EoE to younger children For the first time, an intervention is available to treat esinophilic esophagitis (EoE) in young children. The disease causes damaging inflammation to the esophagus, making it difficult to eat and swallow, but dupilumab (Dupixent—Regeneron/Sanofi) alleviates EoE by suppressing part of the inflammatory pathway. FDA initially approved the monoclonal antibody in 2022 for individuals aged 12 years and older and weighing at least 40 kilograms (kg). Based on results from the Phase III EoE KIDS trial, the regulator has now expanded that approval to now include children aged 1-11 years weighing at least 15 kg. Findings showed that 66% of children who took higher-dose dupilumab had achieved histologic disease remission at 16-week followup vs. just 3% of children randomized to the placebo group. The safety profile — including risk for arthralgia and for certain types of infections — was in line with what was observed in older children and adults taking dupilumab, and histologic remission was sustained at 52 weeks, researchers reported. https://buff.ly/3UbQBIx
FDA Expands Dupilumab for EoE to Younger Children
medscape.com
To view or add a comment, sign in
-
FDA expands dupilumab for EoE to younger children For the first time, an intervention is available to treat esinophilic esophagitis (EoE) in young children. The disease causes damaging inflammation to the esophagus, making it difficult to eat and swallow, but dupilumab (Dupixent—Regeneron/Sanofi) alleviates EoE by suppressing part of the inflammatory pathway. FDA initially approved the monoclonal antibody in 2022 for individuals aged 12 years and older and weighing at least 40 kilograms (kg). Based on results from the Phase III EoE KIDS trial, the regulator has now expanded that approval to now include children aged 1-11 years weighing at least 15 kg. Findings showed that 66% of children who took higher-dose dupilumab had achieved histologic disease remission at 16-week followup vs. just 3% of children randomized to the placebo group. The safety profile — including risk for arthralgia and for certain types of infections — was in line with what was observed in older children and adults taking dupilumab, and histologic remission was sustained at 52 weeks, researchers reported. https://buff.ly/3UbQBIx
FDA Expands Dupilumab for EoE to Younger Children
medscape.com
To view or add a comment, sign in
-
FDA expands dupilumab for EoE to younger children For the first time, an intervention is available to treat esinophilic esophagitis (EoE) in young children. The disease causes damaging inflammation to the esophagus, making it difficult to eat and swallow, but dupilumab (Dupixent—Regeneron/Sanofi) alleviates EoE by suppressing part of the inflammatory pathway. FDA initially approved the monoclonal antibody in 2022 for individuals aged 12 years and older and weighing at least 40 kilograms (kg). Based on results from the Phase III EoE KIDS trial, the regulator has now expanded that approval to now include children aged 1-11 years weighing at least 15 kg. Findings showed that 66% of children who took higher-dose dupilumab had achieved histologic disease remission at 16-week followup vs. just 3% of children randomized to the placebo group. The safety profile — including risk for arthralgia and for certain types of infections — was in line with what was observed in older children and adults taking dupilumab, and histologic remission was sustained at 52 weeks, researchers reported. https://buff.ly/3UbQBIx
FDA Expands Dupilumab for EoE to Younger Children
medscape.com
To view or add a comment, sign in
-
FREE online symposium on the tick-borne disease Alpha-Gal Syndrome on Feb. 10, 2024, from 9-3 EST. Presented by Tick Borne Conditions United and the University of North Carolina at Chapel Hill School of Medicine. Earn six AMA PRA Category 1 Credits(TM)! Alpha-Gal Syndrome is an allergic reaction to the alpha-gal sugar molecule found in "red meat" such as been, lamb, pork, and venison. It can also be found in products that contain mammal ingredients (including some medications, cosmetics, vaccines, gelatin, and milk products). Symptoms include hives, anaphylaxis, gastrointestinal problems, and swelling. There is a strong association with tick bites, most commonly the Lone Star tick. If you develop signs of anaphylaxis (difficulty breathing, throat closure, rapid, weak pulse, dizziness, inability to swallow, full body redness and warmth), seek emergency treatment. https://ow.ly/3bu350QzeFg
Register Now for the Virtual Alpha-gal Syndrome Symposium
https://www.tbcunited.org
To view or add a comment, sign in
-
FDA expands dupilumab for EoE to younger children For the first time, an intervention is available to treat esinophilic esophagitis (EoE) in young children. The disease causes damaging inflammation to the esophagus, making it difficult to eat and swallow, but dupilumab (Dupixent—Regeneron/Sanofi) alleviates EoE by suppressing part of the inflammatory pathway. FDA initially approved the monoclonal antibody in 2022 for individuals aged 12 years and older and weighing at least 40 kilograms (kg). Based on results from the Phase III EoE KIDS trial, the regulator has now expanded that approval to now include children aged 1-11 years weighing at least 15 kg. Findings showed that 66% of children who took higher-dose dupilumab had achieved histologic disease remission at 16-week followup vs. just 3% of children randomized to the placebo group. The safety profile — including risk for arthralgia and for certain types of infections — was in line with what was observed in older children and adults taking dupilumab, and histologic remission was sustained at 52 weeks, researchers reported. https://lnkd.in/dpGiHUFF
FDA Expands Dupilumab for EoE to Younger Children
medscape.com
To view or add a comment, sign in
-
Combining data from three pediatric asthma studies (#Syspharmpedia #UBIOPRED, #PANDA) we showed that metabolites in exhaled breath might enable asthma control classification in children. If we are able to use this non invasive biomarker to predict whether a child is at risk for an excacerbation this should stimulate further development of exhaled metabolites-based point-of-care tests in asthma. Optimizing treatment according to asthma control will improve the quality of life and lung health. Proud of Shariyar and the rest of the team for publishing these interesting results in the Blue Journal. https://lnkd.in/ew4e-dtz
Exhaled Volatile Organic Compounds for Asthma Control Classification in Children with Moderate to Severe Asthma: Results from the SysPharmPediA Study
atsjournals.org
To view or add a comment, sign in
-
Chief Executive Officer at JobRx | Top 1% Industry SSI rank on LinkedIn | Top 1% Network SSI rank on LinkedIn
FDA expands dupilumab for EoE to younger children For the first time, an intervention is available to treat esinophilic esophagitis (EoE) in young children. The disease causes damaging inflammation to the esophagus, making it difficult to eat and swallow, but dupilumab (Dupixent—Regeneron/Sanofi) alleviates EoE by suppressing part of the inflammatory pathway. FDA initially approved the monoclonal antibody in 2022 for individuals aged 12 years and older and weighing at least 40 kilograms (kg). Based on results from the Phase III EoE KIDS trial, the regulator has now expanded that approval to now include children aged 1-11 years weighing at least 15 kg. Findings showed that 66% of children who took higher-dose dupilumab had achieved histologic disease remission at 16-week followup vs. just 3% of children randomized to the placebo group. The safety profile — including risk for arthralgia and for certain types of infections — was in line with what was observed in older children and adults taking dupilumab, and histologic remission was sustained at 52 weeks, researchers reported. https://buff.ly/3UbQBIx
FDA Expands Dupilumab for EoE to Younger Children
medscape.com
To view or add a comment, sign in